ArticleQuantitative imaging in medicine and surgery2025
Ultrafast breast DCE-MRI: comparative analysis of semi-quantitative and pharmacokinetic parameters with gadoterate meglumine versus gadobutrol in malignant lesions and background parenchymal enhancement.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: There is increasing interest in high temporal resolution imaging techniques in breast magnetic resonance imaging (MRI) for breast cancer detection. The purpose of this study was to compare diagnostic performance and kinetic characteristics of gadoterate meglumine (Dotarem Methods: Ultrafast DCE-MRI acquisition is a high temporal resolution (3.5-4.6 seconds) imaging technique used during the first minute following contrast injection to obtain three-dimensional (3D) whole breast images. All ultrafast images were motion-corrected by a non-rigid registration method. This retrospective study evaluated 60 lesions enhanced with Dotarem and 34 with Gadavist. Semi-automatic volumetric segmentation of the lesions was performed with 3D Slicer. Signal enhancement ratio over time was fitted with an empirical mathematic model (EMM) by using each voxel within the lesion and selected normal parenchymal regions of interest (ROIs). Quantitative pharmacokinetic parameters, including K Results: A total of 94 histopathologically confirmed breast lesions were analyzed, comprising 60 Dotarem-enhanced and 34 Gadavist-enhanced lesions. Gadavist demonstrated a steeper early wash-in slope (≈60% Conclusions: In ultrafast breast DCE-MRI, Gadavist demonstrated stronger early enhancement kinetics, whereas Dotarem provided improved tumor-to-BPE contrast and higher sensitivity for select kinetic parameters. These findings underscore the importance of tailoring contrast agent selection to specific diagnostic goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.